{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:53:32Z","timestamp":1782820412494,"version":"3.54.5"},"reference-count":88,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jefferson College of Pharmacy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Protein arginine methyltransferase 5 (PRMT5) mediates arginine methylation of a wide range of proteins and plays context-dependent oncogenic or tumor-suppressive roles. In cancer, PRMT5 represses several tumor suppressor genes, including E-cadherin, TP53BP1, ST7, PTEN, and RB (retinoblastoma). Elevated PRMT5 expression has been reported across multiple cancer types, notably triple-negative breast cancer (TNBC). In TNBC, high PRMT5 levels are associated with enhanced cancer stem cell self-renewal, increased tumor growth and metastasis, and reduced patient survival. Mechanistically, PRMT5 promotes breast cancer stem cell maintenance and proliferation through stabilization of the transcription factors KLF4 and KLF5. Disruption of the PRMT5\u2013KLF4 axis results in significant tumor reduction in TNBC models. Moreover, increased PRMT5 expression has been linked to resistance to chemotherapy and immunotherapy in TNBC. Notably, PRMT5 inhibitors demonstrate synergistic anticancer activity when combined with inhibitors of key oncogenic signaling pathways, including EGFR, PARP, and AKT. While several PRMT5 inhibitors are currently being evaluated in clinical trials for other malignancies, no clinical trials have yet been initiated specifically for TNBC.<\/jats:p>","DOI":"10.3390\/biom16060916","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:01:17Z","timestamp":1782813677000},"page":"916","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PRMT5 as a Key Driver of Stemness and Metastatic Potential in Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Jae Jin","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauli","family":"Maniar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Ghane","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-7855","authenticated-orcid":false,"given":"Ashakumary","family":"Lakshmikuttyamma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications\u2014Cause and consequence of genome function","volume":"23","author":"Burton","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.bbagen.2008.12.006","article-title":"Histone modification patterns and epigenetic codes","volume":"1790","author":"Lennartsson","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0955-0674(03)00013-9","article-title":"Histone and chromatin cross-talk","volume":"15","author":"Fischle","year":"2003","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2143","article-title":"Regulation of histone methylation by demethylimination and demethylation","volume":"8","author":"Klose","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00018-009-0010-x","article-title":"The protein arginine methyltransferase family: An update about function, new perspectives and the physiological role in humans","volume":"66","author":"Wolf","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00018-019-03145-x","article-title":"Protein arginine methyltransferases: Insights into the enzyme structure and mechanism at the atomic level","volume":"76","author":"Tewary","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"118754","DOI":"10.1016\/j.biopha.2025.118754","article-title":"Targeting PRMT5 in cancer: Mechanistic insights and clinical progress","volume":"193","author":"Lee","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hussain, T., Awasthi, S., Shahid, F., Yi, S.S., Sahni, N., and Aldaz, C.M. (2025). Therapeutic potential of PRMT1 as a critical survival dependency target in multiple myeloma. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15104-w"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Motolani, A., Martin, M., Sun, M., and Lu, T. (2021). The Structure and Functions of PRMT5 in Human Diseases. Life, 11.","DOI":"10.3390\/life11101074"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s40364-025-00860-5","article-title":"Arginine methylation in cancer: Mechanisms and therapeutic implications","volume":"13","author":"Xu","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","article-title":"PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies","volume":"3","author":"Carter","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/onc.2016.205","article-title":"A TGF\u03b2-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Liang, Z., Wen, C., Jiang, H., Ma, S., and Liu, X. (2021). Protein Arginine Methyltransferase 5 Functions via Interacting Proteins. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.725301"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1441628","DOI":"10.1080\/23723556.2018.1441628","article-title":"Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?","volume":"5","author":"Chiang","year":"2018","journal-title":"Mol. Cell. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1101\/gad.606110","article-title":"Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency","volume":"24","author":"Tee","year":"2010","journal-title":"Genes Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1541-7786.MCR-24-0233","article-title":"PRMT5 Maintains Tumor Stem Cells to Promote Pediatric High-Grade Glioma Tumorigenesis","volume":"23","author":"DeSisto","year":"2025","journal-title":"Mol. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.exphem.2016.03.009","article-title":"Arginine methyltransferases in normal and malignant hematopoiesis","volume":"44","author":"Greenblatt","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10732748211050583","DOI":"10.1177\/10732748211050583","article-title":"Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis","volume":"28","author":"Liang","year":"2021","journal-title":"Cancer Control."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"RP99225","DOI":"10.7554\/eLife.99225","article-title":"Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment","volume":"13","author":"Zhang","year":"2026","journal-title":"eLife"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101796","DOI":"10.1016\/j.gendis.2025.101796","article-title":"Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors","volume":"13","author":"Song","year":"2025","journal-title":"Genes Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/BJ20120768","article-title":"Protein arginine methyltransferase 5 is essential for growth of lung cancer cells","volume":"446","author":"Gu","year":"2012","journal-title":"Biochem. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1746-1596-8-201","article-title":"Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors","volume":"8","author":"Shilo","year":"2013","journal-title":"Diagn. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s42003-024-06290-7","article-title":"PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth","volume":"7","author":"Abe","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.18632\/aging.204826","article-title":"PRMT5 facilitates angiogenesis and EMT via HIF-1\u03b1\/VEGFR\/Akt signaling axis in lung cancer","volume":"15","author":"Zheng","year":"2023","journal-title":"Aging"},{"key":"ref_27","first-page":"536","article-title":"Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells","volume":"40","author":"Jeon","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1111\/jcmm.16436","article-title":"PRMT5 promotes colorectal cancer growth by interaction with MCM7","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","article-title":"Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma","volume":"74","author":"Yan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-014-1419-0","article-title":"Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro","volume":"118","author":"Han","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/onc.2016.199","article-title":"PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells","volume":"36","author":"Russell","year":"2017","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/neuonc\/nox206","article-title":"PRMT5 as a druggable target for glioblastoma therapy","volume":"20","author":"Welker","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Martinez, S., Sentis, S., Poulard, C., Tr\u00e9dan, O., and Le Romancer, M. (2024). Role of PRMT1 and PRMT5 in Breast Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168854"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-017-4597-6","article-title":"PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer","volume":"168","author":"Wang","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.2147\/OTT.S239730","article-title":"PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR\u03b1\/NF-\u03baBp65 Pathway","volume":"13","author":"Han","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/jcmm.16260","article-title":"Protein arginine methyltransferase 5 (PRMT5) activates WNT\/\u03b2-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3","volume":"25","author":"Shailesh","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1010428317695917","DOI":"10.1177\/1010428317695917","article-title":"Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer","volume":"39","author":"Wu","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Davey, M.G., Hynes, S.O., Kerin, M.J., Miller, N., and Lowery, A.J. (2021). Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174455"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/1873-3468.12360","article-title":"Measuring relative utilization of aerobic glycolysis in breast cancer cells by positional isotopic discrimination","volume":"590","author":"Yang","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1038\/ncomms9419","article-title":"Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis","volume":"6","author":"Hu","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41420-023-01416-y","article-title":"KLF4 transcription factor in tumorigenesis","volume":"9","author":"He","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13046-022-02400-7","article-title":"The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression","volume":"41","author":"Zhang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41467-024-46495-2","article-title":"PRMT5 is an actionable therapeutic target in CDK4\/6 inhibitor-resistant ER+\/RB-deficient breast cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1158\/0008-5472.CAN-11-0458","article-title":"Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4","volume":"71","author":"Powers","year":"2011","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","article-title":"PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression","volume":"21","author":"Chiang","year":"2017","journal-title":"Cell Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41388-024-03264-1","article-title":"PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells","volume":"44","author":"Gillespie","year":"2025","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/cam4.2114","article-title":"Protein arginine methyltransferase 5, A novel therapeutic target for triple-negative breast cancers","volume":"8","author":"Vinet","year":"2019","journal-title":"Cancer Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ebiom.2019.05.011","article-title":"A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy","volume":"44","author":"Zhou","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117145","DOI":"10.1016\/j.taap.2024.117145","article-title":"Protein arginine methyltransferase 5 confers the resistance of triple-negative breast cancer to nanoparticle albumin-bound paclitaxel by enhancing autophagy through the dimethylation of ULK1","volume":"493","author":"Kong","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymeth.2019.09.007","article-title":"Using proximity ligation assay to detect protein arginine methylation","volume":"175","author":"Poulard","year":"2020","journal-title":"Methods"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e202302009","DOI":"10.26508\/lsa.202302009","article-title":"PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer","volume":"6","author":"Noureddine","year":"2023","journal-title":"Life Sci. Alliance."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1021\/acs.jmedchem.5c02570","article-title":"Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer","volume":"69","author":"Cheng","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1038\/s41418-021-00793-0","article-title":"Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12032-025-03119-z","article-title":"miR-770-5p: A novel molecular target regulating KLF4\/EGFR signaling through PRMT5 interaction","volume":"42","author":"Noyan","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13058-020-01305-7","article-title":"KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene","volume":"22","author":"Roberts","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.chembiol.2024.08.003","article-title":"A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e006890","DOI":"10.1136\/jitc-2023-006890","article-title":"PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis","volume":"11","author":"Wang","year":"2023","journal-title":"J. Immunother. Cancer."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-024-03237-y","article-title":"Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","volume":"43","author":"Guo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36766","DOI":"10.1038\/s41598-025-20696-1","article-title":"PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1\/2 and MTAP status in breast cancer cells","volume":"15","author":"Suresh","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101326","DOI":"10.1016\/j.xcrm.2023.101326","article-title":"PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition","volume":"4","author":"Li","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e05787","DOI":"10.1002\/advs.202505787","article-title":"Interferon-Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple-Negative Breast Cancer","volume":"13","author":"Zhang","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_62","first-page":"5094","article-title":"Conflicting roles of EGFR expression by subtypes in breast cancer","volume":"11","author":"Oshi","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_63","first-page":"785","article-title":"Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR\/HER2 Inhibitors in Triple-Negative Breast Cancers","volume":"15","author":"Dakroub","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/ers.11.38","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension","volume":"5","author":"Klinger","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.ymthe.2022.03.003","article-title":"PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41467-021-23833-2","article-title":"PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis","volume":"12","author":"Yin","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/cas.70338","article-title":"Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways and Potentiates Chemotherapy Efficacy in TNBC","volume":"117","author":"Thiebaut","year":"2026","journal-title":"Cancer Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/blood-2019-128998","article-title":"Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma","volume":"134","author":"Sloan","year":"2019","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1182\/bloodadvances.2023009906","article-title":"PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma","volume":"7","author":"Hwang","year":"2023","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/acsmedchemlett.8b00014","article-title":"LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity","volume":"9","author":"Bonday","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41467-021-21204-5","article-title":"PRMT5 inhibition disrupts splicing and stemness in glioblastoma","volume":"12","author":"Sachamitr","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Kuplast","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"108286","DOI":"10.1016\/j.exer.2020.108286","article-title":"EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma","volume":"202","author":"Liu","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-019-03274-0","article-title":"The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma","volume":"145","author":"Holmes","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/1759-7714.14921","article-title":"PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC","volume":"14","author":"Shen","year":"2023","journal-title":"Thorac. Cancer."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.7150\/thno.59605","article-title":"PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"eaaz5683","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hu, R., Zhou, B., Chen, Z., Li, S., Bai, J., Zhang, Y., Sun, Y., Wang, G., Xu, H., and Wang, Z. (2022). PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.722188"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review","volume":"5","author":"Feustel","year":"2022","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20406207241275376","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.annonc.2025.08.3757","article-title":"Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers","volume":"36","author":"Gounder","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/psp4.12882","article-title":"PK\/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor","volume":"12","author":"Guo","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102961","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"107390","DOI":"10.1016\/j.leukres.2023.107390","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"134","author":"Haque","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41375-025-02515-8","article-title":"Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies","volume":"39","author":"Bewersdorf","year":"2025","journal-title":"Leukemia"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/916\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:31:28Z","timestamp":1782819088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":88,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["biom16060916"],"URL":"https:\/\/doi.org\/10.3390\/biom16060916","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]}}}